Abstract:Aim: To discover novel ligands of estrogen receptor (ER) β using pharmacophore mapping and structure-based screening. Methods: A computer-aided strategy combining pharmacophore mapping and structure-based screening was used to screen the Maybridge and Enamine databases. Yeast two-hybrid (Y2H) assay was used to detect the activity and selectivity of the chosen compounds. The transcriptional activities of the chosen compounds were demonstrated with luciferase reporter assays. The anti-proliferative effects of ER antagonists against MCF-7 and MDA-MB-231 breast cancer cells were examined using MTT assay, and the mechanisms of action were analyzed with flow cytometry analysis and Western blotting. Results: Through in silico screen, 95 compounds were chosen for testing in Y2H assay, which led to 20 potent ligands, including 10 agonists, 8 antagonists and 2 partial agonists with EC 50 or IC 50 values at μmol/L. Furthermore, 6 agonists exhibited absolute selectivity for ERβ, and 3 agonists showed higher selectivity for ERβ. The agonists 1g and 1h (10, 25, and 50 μmol/L) dose-dependently increased ER transcriptional activities, whereas the antagonists 2a and 2d (10, 25, and 50 μmol/L) caused dose-dependent inhibition on the activities. The antagonists and partial agonists at 100 μmol/L suppressed the proliferation of ERα positive MCF-7 cells and ERβ positive MDA-MB-231 cells, but were more effective against MDA-MB-231 cells. Treatment of MDA-MB-231 cells with antagonists 2a and 2d (25 and 50 μmol/L) dose-dependently increased the population of cells in the S phase. Both 2a and 2d treatment dose-dependently decreased the expression levels of cyclin A and CDK2. Meanwhile, the downregulation of cyclin E was only caused by 2d , while 2a treatment did not cause significant changes in the protein levels of cyclin E. Conclusion: The selective ligands discovered in this study are promising drug candidates to be used as molecular probes to explore the differences between ERα and ERβ.

Estrogen Receptor Ligands. Part 3: the SAR of Dihydrobenzoxathiin SERMs

3d-Qsar And Docking Studies Of Estrogen Compounds Based On Estrogen Receptor Beta

Molecular Docking, Molecular Dynamics Simulation, and Structure-Based 3D-QSAR Studies on the Aryl Hydrocarbon Receptor Agonistic Activity of Hydroxylated Polychlorinated Biphenyls.

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Estrogen Receptor Ligands. Part 10: Chromanes: Old Scaffolds for New SERAMs

Prenylflavonoids as nonsteroidal phytoestrogens and related structure-activity relationships.

Investigation of the diastereomerism of dihydrobenzoxathiin SERMs for ER alpha by molecular modeling

In Silico Prediction of Estrogen Receptor Subtype Binding Affinity and Selectivity Using 3D-QSAR and Molecular Docking

Discovery and structure-activity analysis of selective estrogen receptor modulators via similarity-based virtual screening.

Development of Thieno[3 ',2 ':5,6]Thiopyrano[4,3-C]pyrazole-3-carboxamide Derivatives As the Estrogen Receptor Ligands: Synthesis, Characterization and Biological Activity

The Estrogen Receptor Relative Binding Affinities of 188 Natural and Xenochemicals: Structural Diversity of Ligands.

Selective Ligands of Estrogen Receptor Β Discovered Using Pharmacophore Mapping and Structure-Based Virtual Screening.

Synthesis and Estrogen-Like Activity of Resveratrol Analogues

Design, Synthesis and Biological Evaluation of Novel Indone Derivatives As Selective ERβ Modulators

Novel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and Dithiobenzanilides

Structure-Activity Relationships For A Large Diverse Set Of Natural, Synthetic, And Environmental Estrogens

Interactions of bisphenol diglycidyl ethers with estrogen receptors α: Fluorescence polarization, reporter gene, and molecular modeling investigations

Integrated "3+1" oxorhenium(V) complexes as estrogen mimics

Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations.

Discovery of Thiochroman Derivatives as Potent, Oral Selective Estrogen Receptor Degraders and Antagonists for the Treatment of Endocrine-Resistant Breast Cancer

Discovery of natural estrogen receptor modulators with structure-based virtual screening.